Head-To-Head Contrast: Grail (GRAL) & The Competition

Grail (NASDAQ:GRAL) is one of 48 publicly-traded companies in the “Medical laboratories” industry, but how does it contrast to its competitors? We will compare Grail to related businesses based on the strength of its valuation, dividends, analyst recommendations, institutional ownership, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and recommmendations for Grail and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grail	0	3	1	0	2.25
Grail Competitors	364	1434	2413	42	2.50

Grail presently has a consensus target price of $31.50, indicating a potential downside of 21.07%. As a group, “Medical laboratories” companies have a potential upside of 1,373.85%. Given Grail’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Grail has less favorable growth aspects than its competitors.

Profitability

This table compares Grail and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grail	N/A	N/A	N/A
Grail Competitors	-3,479.68%	-975.07%	-26.59%

Valuation & Earnings

This table compares Grail and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grail	$125.60 million	N/A	-0.65
Grail Competitors	$1.05 billion	-$110.55 million	-7.97

Grail’s competitors have higher revenue, but lower earnings than Grail. Grail is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

47.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 1.9% of Grail shares are owned by insiders. Comparatively, 16.8% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Grail competitors beat Grail on 7 of the 11 factors compared.

Grail Company Profile

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.